CA2828041C - Methods and compositions for treating or preventing symptoms of hormonal variations - Google Patents

Methods and compositions for treating or preventing symptoms of hormonal variations Download PDF

Info

Publication number
CA2828041C
CA2828041C CA2828041A CA2828041A CA2828041C CA 2828041 C CA2828041 C CA 2828041C CA 2828041 A CA2828041 A CA 2828041A CA 2828041 A CA2828041 A CA 2828041A CA 2828041 C CA2828041 C CA 2828041C
Authority
CA
Canada
Prior art keywords
dextromethorphan
symptoms
dextrorphan
salts
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2828041A
Other languages
English (en)
French (fr)
Other versions
CA2828041A1 (en
Inventor
George E. Royster, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERVENT PHARMACEUTICALS LLC
Original Assignee
FERVENT PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERVENT PHARMACEUTICALS LLC filed Critical FERVENT PHARMACEUTICALS LLC
Publication of CA2828041A1 publication Critical patent/CA2828041A1/en
Application granted granted Critical
Publication of CA2828041C publication Critical patent/CA2828041C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2828041A 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations Active CA2828041C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02
US61/309,638 2010-03-02
PCT/US2011/026650 WO2011109367A2 (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Publications (2)

Publication Number Publication Date
CA2828041A1 CA2828041A1 (en) 2011-09-09
CA2828041C true CA2828041C (en) 2018-04-17

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2828041A Active CA2828041C (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Country Status (12)

Country Link
US (1) US20110218213A1 (enExample)
EP (1) EP2542241B1 (enExample)
JP (1) JP5839362B2 (enExample)
CN (1) CN102858343B (enExample)
AU (3) AU2011223807B2 (enExample)
BR (1) BR112012022052B1 (enExample)
CA (1) CA2828041C (enExample)
EA (1) EA027350B1 (enExample)
ES (1) ES2574210T3 (enExample)
IL (2) IL221706A (enExample)
PL (1) PL2542241T3 (enExample)
WO (1) WO2011109367A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
JP6038416B1 (ja) * 2015-04-07 2016-12-07 株式会社明治 火照り抑制剤
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
EP3958862A4 (en) * 2019-04-22 2023-01-25 Robert L. Knobler NON-HORMONIC HOT FLASH TREATMENT
US20220401366A1 (en) * 2019-11-15 2022-12-22 Consegna Pharma, Inc. Long acting nmda antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP2283821A1 (en) * 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
NZ517044A (en) * 1999-07-22 2004-02-27 Univ Rochester Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
EP1534258A2 (en) * 2002-08-15 2005-06-01 Wyeth AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
MX2008000248A (es) * 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos.
JP5528705B2 (ja) * 2005-12-13 2014-06-25 トリニティ ラボラトリーズ インコーポレイテッド ヒトにおける早漏を治療するための方法
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
ES2423485T3 (es) * 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
CN102223893B (zh) * 2008-07-22 2014-07-16 曼诺吉尼克斯公司 治疗与绝经、激素改变和关节炎相关的症状的组合物和方法

Also Published As

Publication number Publication date
ES2574210T3 (es) 2016-06-15
BR112012022052A2 (pt) 2020-07-07
WO2011109367A4 (en) 2012-02-23
AU2016213776B2 (en) 2018-04-12
IL253853B (en) 2019-05-30
CA2828041A1 (en) 2011-09-09
EA201290851A1 (ru) 2013-04-30
WO2011109367A3 (en) 2011-12-29
JP5839362B2 (ja) 2016-01-06
CN102858343B (zh) 2015-11-25
EP2542241A4 (en) 2013-11-06
AU2016213776A1 (en) 2016-09-01
AU2011223807B2 (en) 2016-05-12
AU2011223807A1 (en) 2012-10-18
IL221706A (en) 2017-08-31
CN102858343A (zh) 2013-01-02
WO2011109367A2 (en) 2011-09-09
EA027350B1 (ru) 2017-07-31
BR112012022052B1 (pt) 2021-06-29
EP2542241A2 (en) 2013-01-09
AU2018205147A1 (en) 2018-08-02
PL2542241T3 (pl) 2016-12-30
EP2542241B1 (en) 2016-04-27
IL253853A0 (en) 2017-09-28
JP2013521297A (ja) 2013-06-10
US20110218213A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US9457022B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
AU2016213776B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
EP2101781B1 (en) Method for treating or preventing symptoms of hormonal variations
US20110124617A1 (en) Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
US20040180879A1 (en) Novel method of treating vasomotor symptoms
WO2008037045A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
RS57150B1 (sr) Lečenje menopauzalnih valunga ropinirolom i tizanidinom
EA011926B1 (ru) Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260306

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260306

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260413